PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7282559

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
ASYMCHEM, INC.	03/28/2022

RECEIVING PARTY DATA

Name:	CORCEPT THERAPEUTICS INCORPORATED	
Street Address:	149 COMMONWEALTH DRIVE	
City:	MENLO PARK	
State/Country:	CALIFORNIA	
Postal Code:	94025	

PROPERTY NUMBERS Total: 2

Property Type	Number
Application Number:	17560048
PCT Number:	US2164947

CORRESPONDENCE DATA

Fax Number: (415)432-6001

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4154326000

Email: TMIngrande@mintz.com

Correspondent Name: MINTZ LEVIN COHN FERRIS GLOVSKY & POPEO, P.C.

Address Line 1: ONE FINANCIAL CENTER

Address Line 4: BOSTON, MASSACHUSETTS 02111

ATTORNEY DOCKET NUMBER:	052691-505001US505001WO	
NAME OF SUBMITTER:	ALEXANDER R. TRIMBLE	
SIGNATURE:	/ALEXANDER R. TRIMBLE/	
DATE SIGNED:	04/15/2022	

Total Attachments: 3

 $source=052691-505001US_-505001WO_2022-04-15_Assignment_Asymchem\ to\ Corcept\#page1.tif\ source=052691-505001US_-505001WO_2022-04-15_Assignment_Asymchem\ to\ Corcept\#page2.tif\ source=052691-505001US_-505001WO_2022-04-15_Assignment_Asymchem\ to\ Corcept\#page3.tif\ source=052691-505001WO_2022-04-15_Assignment_Asymchem\ to\ Corcept\#page3.tif\ source=052691-505001WO_2022-04-15_Assignment_Asymchem\ to\ Corcept\#page3.tif\ source=052691-505001WO_2022-04-15_Assignment_Asymchem\ to\ Corcept\#page3.tif\ source=052691-505001WO_2022-04-15_Assignment_Asymchem\ to\ Corcept\#page3.tif\ source=052691-505001WO_2022-04-15_Asymchem\ to\ Corcept\#$

PATENT 507235640 REEL: 059612 FRAME: 0811

ASSIGNMENT (Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility (provisional or non-provisional) or design patent application or PCT application entitled:

"METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS"

filed with the U.S. Patent & Trademark Office on December 22, 2021 and assigned serial no. 17/560,048 and

filed with the U.S. Patent & Trademark Office as Receiving Office on December 22, 2021 and assigned PCT International Patent Application No. PCT/US21/64947.

For other good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

- Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to Corcept Therapeutics Incorporated (which also does business as "Corcept Therapeutics, Inc."), a corporation of the State of Delaware having a principal place of business at 149 Commonwealth Drive, Menlo Park, CA 94025 ("Assignee"), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above- referenced patent applications, implicitly or explicitly;
 - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent applications, all applications based in whole or in part upon the above-referenced patent applications, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent applications;
 - (e) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim

PATENT REEL: 059612 FRAME: 0812

ASSIGNMENT U.S. Serial No. 17/560,048 PCT Application No. PCT/US21/64947 Attorney Docket Nos. 052691-505001US, -505001WO Page 2 of 3

> priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own
- 2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
- 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
- 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us [me], as well as our [my] heirs, legal representatives, and assigns.
- 5. Promise and affirm that we [I] have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

IN TESTIMONY WHEREOF, Assignor has signed his name on the date

indicated.

Assignor:

Asymchem, Inc.

600 Airport Blvd, Suite 1000 Morrisville, NC 27560 USA

Signature:

Title: President

Date: March 28, 2022

ASSIGNMENT U.S. Serial No. 17/560,048 PCT Application No. PCT/US21/64947 Attorney Docket Nos. 052691-505001US, -505001WO Page 3 of 3

DEED OF ACCEPTANCE

I (we), Corcept Therapeutics Incorporated, with offices at 149 Commonwealth

Drive, Menlo Park, CA 94025, USA declare that I (we) accept the rights given in the attached

Assignment.

Signature:

Name:

Shamack Ghose

Title:

V/ of I/

Date

122705933v,1

PATENT REEL: 059612 FRAME: 0814

RECORDED: 04/15/2022